OncoMatch/Clinical Trials/NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Is NCT05643742 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CTX112 for b-cell lymphoma.
Treatment: CTX112 — This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiac function
Adequate renal, liver, cardiac and pulmonary organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University · St Louis, Missouri
- SCRI · San Antonio, Texas
- University of Utah · Salt Lake City, Utah
- University of Kansas · Westwood, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05643742 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify